Contact us
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...
Latest news
Learn more about how Angiex is addressing the hallmarks of cancer lethality in our latest news posts and press releases.
Press release
14 November 2025
Angiex Completes $31M Financings for Phase 1 Clinical Development of AGX101
Angiex Completes Financings Totaling $31M to Support the Phase 1 Clinical Development of AGX101 in Patients with Advanced Solid Tumors
Press release
07 August 2024
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors
Press release
02 November 2023
Press release
22 September 2023
Press release
29 September 2022
Press release
07 September 2022
Press release
18 August 2021
